{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=20", "query": { "intervention": "Control Study Product", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 4228, "total_pages": 423, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T08:00:50.169Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00064441", "title": "FACTS I: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "OPC-6535 Tablets (drug)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 375, "start_date": "2003-05", "completion_date": "2006-05", "has_results": false, "last_update_posted_date": "2012-05-10", "last_synced_at": "2026-10-21T08:00:50.169Z", "location_count": 23, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Santa Ana, California + 18 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Wheat Ridge", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00064441" }, { "nct_id": "NCT02473016", "title": "Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Trigeminal Neuralgia" ], "interventions": [ { "name": "Carbon Dioxide Drug Delivery System (CDDS)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Capnia, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2015-09", "completion_date": "2017-04", "has_results": false, "last_update_posted_date": "2017-11-17", "last_synced_at": "2026-10-21T08:00:50.169Z", "location_count": 6, "location_summary": "Los Angeles, California • Tampa, Florida • New York, New York + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02473016" }, { "nct_id": "NCT03912233", "title": "A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-121", "type": "DRUG" }, { "name": "TEZ", "type": "DRUG" }, { "name": "VX-561", "type": "DRUG" }, { "name": "TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2019-04-30", "completion_date": "2019-12-10", "has_results": true, "last_update_posted_date": "2023-04-20", "last_synced_at": "2026-10-21T08:00:50.169Z", "location_count": 12, "location_summary": "Los Angeles, California • Oakland, California • Lexington, Kentucky + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03912233" }, { "nct_id": "NCT02980133", "title": "Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Fluticasone Propionate", "type": "DRUG" }, { "name": "Fluticasone Propionate/Salmeterol", "type": "DRUG" }, { "name": "Placebo MDPI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "4 Years to 11 Years" }, "enrollment_count": 841, "start_date": "2016-12-28", "completion_date": "2019-04-13", "has_results": true, "last_update_posted_date": "2021-11-09", "last_synced_at": "2026-10-21T08:00:50.169Z", "location_count": 77, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 59 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Corona", "state": "California" }, { "city": "Downey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02980133" }, { "nct_id": "NCT03306316", "title": "Prebiotic in Preterm Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Preterm Infant", "Development, Infant", "Nutrition" ], "interventions": [ { "name": "Prebiotic", "type": "DIETARY_SUPPLEMENT" }, { "name": "Dextrose Control", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Nationwide Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Days", "maximum_age": "10 Days", "sex": "ALL", "summary": "7 Days to 10 Days" }, "enrollment_count": 44, "start_date": "2018-07-04", "completion_date": "2023-12-31", "has_results": false, "last_update_posted_date": "2024-02-08", "last_synced_at": "2026-10-21T08:00:50.169Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03306316" }, { "nct_id": "NCT04480333", "title": "Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Covid19", "Corona Virus Infection", "Severe Acute Respiratory Syndrome", "Severe Acute Respiratory Infection", "Severe Acute Respiratory Syndrome (SARS) Pneumonia", "Severe Acute Respiratory Syndrome of Upper Respiratory Tract", "Neurodegeneration", "Neuroinflammatory Response" ], "interventions": [ { "name": "Drug: NA-831 - 0.10 mg/kg", "type": "DRUG" }, { "name": "Placebo- 0.10 mg/kg", "type": "DRUG" }, { "name": "Drug: NA-831 - 0.20 mg/kg", "type": "DRUG" }, { "name": "Placebo- 0.20 mg/kg", "type": "DRUG" }, { "name": "Drug: GS-5734 - 1.00 mg/kg", "type": "DRUG" }, { "name": "Placebo- 1.00 mg/kg", "type": "DRUG" }, { "name": "Drug: GS-5734 - 2.00 mg/kg", "type": "DRUG" }, { "name": "Placebo- 2.00 mg/kg", "type": "DRUG" }, { "name": "Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo 0.10 mg + 1.00 mg/kg", "type": "COMBINATION_PRODUCT" }, { "name": "Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo 0.20 mg + 2.00 mg/kg", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Biomed Industries, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "21 Years to 50 Years" }, "enrollment_count": 45, "start_date": "2020-09-15", "completion_date": "2021-03-31", "has_results": false, "last_update_posted_date": "2020-07-21", "last_synced_at": "2026-10-21T08:00:50.169Z", "location_count": 1, "location_summary": "Sunnyvale, California", "locations": [ { "city": "Sunnyvale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04480333" }, { "nct_id": "NCT04592380", "title": "Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dyspnea", "Hypertension", "Acute Heart Failure" ], "interventions": [ { "name": "Stage 1: Clevidipine (double-blinded)", "type": "DRUG" }, { "name": "Stage 1: Placebo (double-blinded)", "type": "DRUG" }, { "name": "Stage 2: Clevidipine (open-label)", "type": "DRUG" }, { "name": "Stage 2: Standard of Care (open-label)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Medicines Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-08", "completion_date": "2016-11", "has_results": false, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-10-21T08:00:50.169Z", "location_count": 9, "location_summary": "Montgomery, Alabama • Tucson, Arizona • St Louis, Missouri + 5 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Brooklyn", "state": "New York" }, { "city": "Brooklyn", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04592380" }, { "nct_id": "NCT01038427", "title": "A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rhinitis, Allergic, Seasonal" ], "interventions": [ { "name": "Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals)", "type": "DRUG" }, { "name": "Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sandoz", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 795, "start_date": "2009-12-02", "completion_date": "2010-02-16", "has_results": true, "last_update_posted_date": "2021-02-03", "last_synced_at": "2026-10-21T08:00:50.169Z", "location_count": 8, "location_summary": "Austin, Texas • Kerrville, Texas • Live Oak, Texas + 3 more", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "Austin", "state": "Texas" }, { "city": "Kerrville", "state": "Texas" }, { "city": "Live Oak", "state": "Texas" }, { "city": "New Braunfels", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01038427" }, { "nct_id": "NCT06453824", "title": "SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Safety and Tolerability" ], "interventions": [ { "name": "MDI-2517", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "MDI Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 48, "start_date": "2024-05-17", "completion_date": "2024-11-11", "has_results": false, "last_update_posted_date": "2025-03-14", "last_synced_at": "2026-10-21T08:00:50.169Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06453824" }, { "nct_id": "NCT01067027", "title": "Control of Colic in Infants by Dietary Supplementation With the Probiotic Lactobacillus Reuteri", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Colic" ], "interventions": [ { "name": "Lactobacillus reuteri", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Children's Investigational Research Program, LLC", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "14 Days", "maximum_age": "60 Days", "sex": "ALL", "summary": "14 Days to 60 Days" }, "enrollment_count": 50, "start_date": "2009-06", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2011-06-29", "last_synced_at": "2026-10-21T08:00:50.169Z", "location_count": 1, "location_summary": "Bentonville, Arkansas", "locations": [ { "city": "Bentonville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01067027" } ] }